<DOC>
	<DOCNO>NCT00413400</DOCNO>
	<brief_summary>This study investigate whether etanercept result improve inflammatory index , glucose tolerance endothelial function patient metabolic syndrome .</brief_summary>
	<brief_title>Study TNF-Antagonism Metabolic Syndrome ( II )</brief_title>
	<detailed_description>Metabolic syndrome increasingly prevalent disorder associate elevated risk type II DM ( diabetes mellitus ) cardiovascular morbidity mortality . A subclinical inflammatory state think contribute pathophysiology metabolic syndrome , insulin resistance , coronary artery disease ( CAD ) . Tumor Necrosis Factor ( TNF ) -alpha inflammatory cytokine increase spectrum inflammatory disease well insulin resistance . TNF-alpha antagonist clinically effective inflammation arthritides , recently show group decrease inflammatory cardiovascular risk marker metabolic syndrome . Data suggest adiponectin , recently discover adipocytokine may protect development insulin resistance atherosclerosis , may downregulated TNF-alpha . In addition , population base study show high level TNF-alpha increase relative risk cardiovascular morbidity rheumatoid arthritis patient treat TNF-alpha blockade appear protect cardiovascular disease . We perform 6-month study administer etanercept , TNF-alpha receptor fusion protein , subject metabolic syndrome investigate effect surrogate marker cardiovascular disease , include inflammatory marker , adiponectin glucose tolerance endothelial function . The result propose study broad implication regard physiological role TNF-alpha inflammatory cascade , cardiovascular index endothelial function .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . Hyperinsulinemia upper quartile nondiabetic population define &gt; = 10 mU/mL ( base Framingham Data , oral communication , James Meigs , MD ) fast glucose 110126 mg/dL 2 . Plus two following : Abdominal obesity define waist hip ratio &gt; 0.90 men &gt; 0.85 woman BMI &gt; 30 kg/m2 Dyslipidemia include serum triglyceride &gt; = 150 mg/dl serum high density lipoprotein ( HDL ) &lt; 0.9 mmol/L men ( 35 mg/dL ) &lt; 1.0 mmol/L ( 39mg/dL ) woman Hypertension define blood pressure &gt; = 140/90 medication 1 . Age &lt; 18 &gt; 60 year 2 . Body mass index ( BMI ) &lt; 30 kg/m2 3 . Positive tuberculosis ( purified protein derivative [ PPD ] ) skin test ( 5mm induration ) screen 4 . Mycobacterial disease treat less 6 month . 5 . Current recurrent infection underlie condition may predispose infection anyone admit hospital due bacteremia , pneumonia serious infection . 6 . Therapy glucocorticoid immunosuppressant time recruitment within past 3 month . 7 . Prior concurrent cyclophosphamide therapy 8 . Use live vaccine 90 day prior , study . 9 . History blood dyscrasia include kind anemia , thrombocytopenia , pancytopenia . Women reversible cause anemia resolve eligible . 10 . Hemoglobin &lt; 11 g/dl 11 . History malignancy ( except patient surgically cure basal cell squamous cell skin cancer eligible ) 12 . History organ transplantation 13 . HIVpositive status determine HIV test screen know history immunosuppressing disease . 14 . Hepatitis B hepatitis C infection detect screening , lupus ( SLE ) , history multiple sclerosis , transverse myelitis , optic neuritis epilepsy 15 . Patients know autoimmune inflammatory condition ( exclude patient stable , treated hypothyroidism ) 16 . Severe comorbidities ( diabetes mellitus require insulin , congestive heart failure ( CHF ) ( EF &lt; 50 % baseline exclusionary ) severity , myocardial infarction ( MI ) , cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) within 3 month screen visit , unstable angina pectoris , oxygendependent severe pulmonary disease 17 . Uncontrolled systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 100 mmHg 18 . Fasting blood glucose &gt; 126 mg/dL 19 . Creatinine &gt; 1.5 20 . Current use insulin , oral antihyperglycemic agent ( include insulin sensitize agent ) . Initiation insulin , oral hypoglycemics , insulin sensitize agent study result discontinuation study . 21 . Initiation statin , niacin , antihypertensive fibrate therapy within 6 week study . Chronic use fibrates , niacin , antihypertensives &gt; 6 week prior study initiation stable dose exclusionary , chronic use statins &gt; 6 month exclusionary . Initiation statin , fibrates , niacin antihypertensive treatment study exclusionary consider analysis ( see Protection risk ) . 22 . Positive pregnancy test lactating females 23 . Women childbearing potential currently use nonhormonal birth control method include barrier method ( intrauterine device [ IUD ] , condom , diaphragm ) abstinence 24 . Subject currently enrol another investigational device drug trial ( ) , subject receive investigational agent ( ) within 28 day baseline visit . 25 . Subjects know hypersensitivity Enbrel component know antibody etanercept 26 . Concurrent sulfasalazine therapy 27 . History recent alcohol substance abuse ( &lt; 1 year ) 28 . Any condition judge patient 's physician cause clinical trial detrimental patient . 29 . History noncompliance therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Inflammation</keyword>
	<keyword>Visceral adiposity</keyword>
	<keyword>TNF</keyword>
	<keyword>Adiponectin</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>endothelial function</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>